董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Jennifer Buell | 女 | Independent Director | 50 | 未披露 | 未持股 | 2025-12-31 |
| Barrett Evans | 男 | Director | 53 | 未披露 | 未持股 | 2025-12-31 |
| Colin Stott | 男 | Director | -- | 未披露 | 未持股 | 2025-12-31 |
| Garo H. Armen | 男 | Executive Chairman of the Board | 73 | 41.12万美元 | 未持股 | 2025-12-31 |
| Brian Corvese | 男 | Independent Director | 68 | 未披露 | 未持股 | 2025-12-31 |
| Timothy R. Wright | 男 | Director | 68 | 未披露 | 未持股 | 2025-12-31 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Andrew Slee | 男 | Chief Development Officer | 75 | 未披露 | 未持股 | 2025-12-31 |
| Robert B. Stein | 男 | Chief Medical Officer | 74 | 未披露 | 未持股 | 2025-12-31 |
| Garo H. Armen | 男 | Executive Chairman of the Board | 73 | 41.12万美元 | 未持股 | 2025-12-31 |
| Alexander K. Arrow | 男 | Chief Financial Officer | 54 | 15.00万美元 | 未持股 | 2025-12-31 |
董事简历
中英对照 | 中文 | 英文- Jennifer Buell
-
Jennifer Buell于2020年7月加入我们的董事会。Buell博士是Agenus，Inc.的总裁兼首席运营官，她此前曾在该公司担任全球研发运营主管、研究主管以及首席通信与对外事务官。Buell博士拥有20年的生物制药研发经验，在通过开发和经验与包括监管机构、投资者和合作者在内的外部利益相关者沟通来推进发现候选药物方面拥有丰富的知识。她拥有成功的研发领导记录，最近任职Agenus公司，在那里她曾领导高性能团队，推动候选人进入诊所，并进行关键联盟合作。加入Agenus公司之前，她曾担任Bristol-Myers Squibb公司的研发运营领导职务，在那里她曾负责Harvard Clinical Research Institute Baim公司的项目和联盟管理，在那里她曾参与行业和政府赞助的临床项目投资组合的发展战略和运营。Buell博士在塔夫茨大学（Tufts University）获得细胞、生化和分子生物化学博士学位，并获得生物统计学硕士学位。
Jennifer Buell, Director, joined on July 18, 2020, filling the open board seat created when Board approved the increase of the size of Board from five to six directors. Dr. Buell serves as the President and Chief Operating Officer of Agen Inc. Since 2013, Dr. Buell has served Agen as the Head of Global R&D operations, Head of Research, and Chief External Affairs and Communications Officer. During her tenure, Dr. Buell advanced the expansion of Agen from a neoantigen vaccine company to a global, fully integrated platform company with a unique pipeline of immune modulating antibodies, adoptive cell therapies, adjuvants, and cancer vaccines. With over 20 years of biopharmaceutical R&D experience, Dr. Buell has a proven record of success in R&D leadership, most recently at Agen, where she has led high performing teams in outpacing large pharmaceutical companies in advancing novel therapies to the clinic through Agen' proprietary pipeline and in collaboration with Incyte, Merck, and Gilead. Prior to joining Agen, Dr. Buell held leadership positions in R&D operations at Bristol Myers Squibb and was later responsible for Programs and Alliances at Harvard Clinical (Baim), where she led the strategy and operations of a portfolio of programs in oncology, neurology, nephrology, and cardiometabolic diseases. Dr. Buell obtained her PhD in Cellular, Biochemical, and Molecular Biochemistry with an MS in Biostatistics from Tufts University in Boston, Massachetts. - Jennifer Buell于2020年7月加入我们的董事会。Buell博士是Agenus，Inc.的总裁兼首席运营官，她此前曾在该公司担任全球研发运营主管、研究主管以及首席通信与对外事务官。Buell博士拥有20年的生物制药研发经验，在通过开发和经验与包括监管机构、投资者和合作者在内的外部利益相关者沟通来推进发现候选药物方面拥有丰富的知识。她拥有成功的研发领导记录，最近任职Agenus公司，在那里她曾领导高性能团队，推动候选人进入诊所，并进行关键联盟合作。加入Agenus公司之前，她曾担任Bristol-Myers Squibb公司的研发运营领导职务，在那里她曾负责Harvard Clinical Research Institute Baim公司的项目和联盟管理，在那里她曾参与行业和政府赞助的临床项目投资组合的发展战略和运营。Buell博士在塔夫茨大学（Tufts University）获得细胞、生化和分子生物化学博士学位，并获得生物统计学硕士学位。
- Jennifer Buell, Director, joined on July 18, 2020, filling the open board seat created when Board approved the increase of the size of Board from five to six directors. Dr. Buell serves as the President and Chief Operating Officer of Agen Inc. Since 2013, Dr. Buell has served Agen as the Head of Global R&D operations, Head of Research, and Chief External Affairs and Communications Officer. During her tenure, Dr. Buell advanced the expansion of Agen from a neoantigen vaccine company to a global, fully integrated platform company with a unique pipeline of immune modulating antibodies, adoptive cell therapies, adjuvants, and cancer vaccines. With over 20 years of biopharmaceutical R&D experience, Dr. Buell has a proven record of success in R&D leadership, most recently at Agen, where she has led high performing teams in outpacing large pharmaceutical companies in advancing novel therapies to the clinic through Agen' proprietary pipeline and in collaboration with Incyte, Merck, and Gilead. Prior to joining Agen, Dr. Buell held leadership positions in R&D operations at Bristol Myers Squibb and was later responsible for Programs and Alliances at Harvard Clinical (Baim), where she led the strategy and operations of a portfolio of programs in oncology, neurology, nephrology, and cardiometabolic diseases. Dr. Buell obtained her PhD in Cellular, Biochemical, and Molecular Biochemistry with an MS in Biostatistics from Tufts University in Boston, Massachetts.
- Barrett Evans
-
巴雷特·埃文斯是EMC2 Capital，LLC的董事总经理，该公司是一家成立于2020年的家族办公室。自2006年起，他还担任过Montecito Capital的总裁。埃文斯先生自2024年起担任Phytanix Bio的首席执行官，自2020年起担任Dryworld Brands，Inc.的执行和董事。在创立Montecito Capital之前，Evans先生是eFund Capital的董事总经理。埃文斯先生曾作为顾问、创始人、执行官和董事担任过众多上市公司和私营公司的成员，他被认为是审计委员会的财务专家。Evans先生为公司带来了多年的公开市场经验和知识。埃文斯先生拥有加州大学圣巴巴拉分校政治学学士学位。
Barrett Evans, Director, is the managing director of EMC2 Capital, LLC, a family office founded in 2020. He has also served as the President of Montecito Capital since 2006. Mr. Evans is a Director and CEO of Phytanix Bio, and a director of Dryworld Brands since 2020. Before founding Montecito Capital, Mr. Evans was the managing director of eFund Capital. Mr. Evans has served as a member of public and private companies as a consultant, founder, executive, and director, and he is considered an audit committee financial expert. Mr. Evans has a bachelor's degree in political science from the University of California, Santa Barbara. - 巴雷特·埃文斯是EMC2 Capital，LLC的董事总经理，该公司是一家成立于2020年的家族办公室。自2006年起，他还担任过Montecito Capital的总裁。埃文斯先生自2024年起担任Phytanix Bio的首席执行官，自2020年起担任Dryworld Brands，Inc.的执行和董事。在创立Montecito Capital之前，Evans先生是eFund Capital的董事总经理。埃文斯先生曾作为顾问、创始人、执行官和董事担任过众多上市公司和私营公司的成员，他被认为是审计委员会的财务专家。Evans先生为公司带来了多年的公开市场经验和知识。埃文斯先生拥有加州大学圣巴巴拉分校政治学学士学位。
- Barrett Evans, Director, is the managing director of EMC2 Capital, LLC, a family office founded in 2020. He has also served as the President of Montecito Capital since 2006. Mr. Evans is a Director and CEO of Phytanix Bio, and a director of Dryworld Brands since 2020. Before founding Montecito Capital, Mr. Evans was the managing director of eFund Capital. Mr. Evans has served as a member of public and private companies as a consultant, founder, executive, and director, and he is considered an audit committee financial expert. Mr. Evans has a bachelor's degree in political science from the University of California, Santa Barbara.
- Colin Stott
-
Colin Stott，董事，现任Alterola Biotech Inc.首席运营官和董事。他曾在从事大麻素疗法开发的公司GW Pharmaceuticals plc担任国际科学事务总监和研发运营总监。在担任研发运营总监的16年期间，他为公司的研发项目做出了贡献，并参与了Sativex的提交和批准流程和Epidiolex.Epidiolex于2018年6月获得美国食品药品监督管理局批准，并于2019年9月获得欧洲药品管理局批准（作为Epidyolex）用于治疗罕见形式的小儿癫痫。最近在GW Pharmaceuticals任职期间，他参与了Epidiolex国际上市的准备工作作为医疗事务团队的一员。Stott先生拥有英国拉夫堡理工大学医药和药物化学理学士（荣誉）学位和Indtrial研究文凭，以及英国卡迪夫大学lSH药学院临床研究研究生文凭。他撰写了20多篇研究论文，是19项国际专利申请的指定发明人。
Colin Stott, Director, is currently the Chief Operating Officer and a director of Alterola Biotech Inc. He previoly held roles as Scientific Affairs Director, International, and R&D Operations Director at GW Pharmaceuticals plc, a company involved in the development of cannabinoid therapeutics. During his 16 years as R&D Operations Director, he contributed to the company's research and development programs and was involved in the submission and approval processes for Sativex and Epidiolex. Epidiolex was approved by the U.S. Food and Drug Administration in June 2018 and by the European Medicines Agency in September 2019 (as Epidyolex) for the treatment of rare forms of pediatric epilepsy. In his most recent role at GW Pharmaceuticals, he worked on preparations for the international launch of Epidiolex as part of the Medical Affairs team. - Colin Stott，董事，现任Alterola Biotech Inc.首席运营官和董事。他曾在从事大麻素疗法开发的公司GW Pharmaceuticals plc担任国际科学事务总监和研发运营总监。在担任研发运营总监的16年期间，他为公司的研发项目做出了贡献，并参与了Sativex的提交和批准流程和Epidiolex.Epidiolex于2018年6月获得美国食品药品监督管理局批准，并于2019年9月获得欧洲药品管理局批准（作为Epidyolex）用于治疗罕见形式的小儿癫痫。最近在GW Pharmaceuticals任职期间，他参与了Epidiolex国际上市的准备工作作为医疗事务团队的一员。Stott先生拥有英国拉夫堡理工大学医药和药物化学理学士（荣誉）学位和Indtrial研究文凭，以及英国卡迪夫大学lSH药学院临床研究研究生文凭。他撰写了20多篇研究论文，是19项国际专利申请的指定发明人。
- Colin Stott, Director, is currently the Chief Operating Officer and a director of Alterola Biotech Inc. He previoly held roles as Scientific Affairs Director, International, and R&D Operations Director at GW Pharmaceuticals plc, a company involved in the development of cannabinoid therapeutics. During his 16 years as R&D Operations Director, he contributed to the company's research and development programs and was involved in the submission and approval processes for Sativex and Epidiolex. Epidiolex was approved by the U.S. Food and Drug Administration in June 2018 and by the European Medicines Agency in September 2019 (as Epidyolex) for the treatment of rare forms of pediatric epilepsy. In his most recent role at GW Pharmaceuticals, he worked on preparations for the international launch of Epidiolex as part of the Medical Affairs team.
- Garo H. Armen
-
Garo H. Armen是Protagenic治疗公司的创始人之一，于2004年9月加入Protagenic治疗公司。Garo H. Armen是Agenus Inc.的董事长兼首席执行官，他在1994年与他人共同创立了一家生物技术公司。从2002年中到2004年，他还担任了成功重组的生物制药公司Elan Corporation，plc的董事会主席。在加入Agenus Inc.之前，Armen博士创立了Armen Partners，这是一家专门从事生物技术和制药公司业务的资金管理公司，并且是1993年创立Immunex Lederle肿瘤学公司这一广为人知的项目的设计者。在更早之前，他是Dean Witter Reynolds研究部高级副总裁，他的职业生涯始于华尔街，在EF Hutton担任分析师和投资银行家。2002年，Armen博士创立了亚美尼亚儿童基金会，这是一个非营利组织，致力于大力重建和振兴贫困的亚美尼亚农村城镇，为儿童和青年提供直接和可持续的利益。由于他的人道主义努力，他于2004年获得埃利斯岛荣誉勋章；由于他在生物技术和医学研究方面取得的成就，他于2006年获得萨宾疫苗研究所颁发的萨宾人道主义奖。Armen博士也是安永会计师事务所2002年纽约市年度生物技术企业家，并于2005年获得黑素瘤研究基金会颁发的希望之翼奖，以表彰他对黑素瘤社区的持续承诺。Armen博士在纽约城市大学研究生中心获得物理化学博士学位，之后他在纽约长岛的Brookhaven国家实验室担任研究员。
Garo H. Armen, Executive Chairman, is one of founders and joined in September 2004. Garo H. Armen is Chairman and Chief Executive Officer of Agen Inc., a biotechnology company he co founded in 1994. From mid 2002 through 2004, he also served as Chairman of the Board of the biopharmaceutical company Elan Corporation, plc, which he successfully restructured. Prior to Agen Inc., Dr. Armen established Armen Partners, a money management firm specializing in biotechnology and pharmaceutical companies and was the architect of the widely publicized creation of the Immunex Lederle oncology biness in 1993. Earlier, he was a senior vice president of research at Dean Witter Reynolds, having begun his career on Wall Street as an analyst and investment banker at EF Hutton. In 2002, Dr. Armen founded the Children of Armenia Fund, a nonprofit organization dedicated to significantly rebuilding and revitalizing impoverished rural Armenian towns to provide immediate and stainable benefits to children and youth. He received the Ellis Island Medal of Honor in 2004 for his humanitarian efforts, and received the Sabin Humanitarian Award from the Sabin Vaccine Institute in 2006 for his achievements in biotechnology and progressing medical research. Dr. Armen was also the Ernst & Young 2002 New York City Biotechnology Entrepreneur of the Year, and received a Wings of Hope Award in 2005 from The Melanoma Research Foundation for his ongoing commitment to the melanoma community. Dr. Armen received a PhD in physical chemistry from the Graduate Center, City University of New York, after which he worked as a research fellow at Brookhaven National Laboratories in Long Island, NY. - Garo H. Armen是Protagenic治疗公司的创始人之一，于2004年9月加入Protagenic治疗公司。Garo H. Armen是Agenus Inc.的董事长兼首席执行官，他在1994年与他人共同创立了一家生物技术公司。从2002年中到2004年，他还担任了成功重组的生物制药公司Elan Corporation，plc的董事会主席。在加入Agenus Inc.之前，Armen博士创立了Armen Partners，这是一家专门从事生物技术和制药公司业务的资金管理公司，并且是1993年创立Immunex Lederle肿瘤学公司这一广为人知的项目的设计者。在更早之前，他是Dean Witter Reynolds研究部高级副总裁，他的职业生涯始于华尔街，在EF Hutton担任分析师和投资银行家。2002年，Armen博士创立了亚美尼亚儿童基金会，这是一个非营利组织，致力于大力重建和振兴贫困的亚美尼亚农村城镇，为儿童和青年提供直接和可持续的利益。由于他的人道主义努力，他于2004年获得埃利斯岛荣誉勋章；由于他在生物技术和医学研究方面取得的成就，他于2006年获得萨宾疫苗研究所颁发的萨宾人道主义奖。Armen博士也是安永会计师事务所2002年纽约市年度生物技术企业家，并于2005年获得黑素瘤研究基金会颁发的希望之翼奖，以表彰他对黑素瘤社区的持续承诺。Armen博士在纽约城市大学研究生中心获得物理化学博士学位，之后他在纽约长岛的Brookhaven国家实验室担任研究员。
- Garo H. Armen, Executive Chairman, is one of founders and joined in September 2004. Garo H. Armen is Chairman and Chief Executive Officer of Agen Inc., a biotechnology company he co founded in 1994. From mid 2002 through 2004, he also served as Chairman of the Board of the biopharmaceutical company Elan Corporation, plc, which he successfully restructured. Prior to Agen Inc., Dr. Armen established Armen Partners, a money management firm specializing in biotechnology and pharmaceutical companies and was the architect of the widely publicized creation of the Immunex Lederle oncology biness in 1993. Earlier, he was a senior vice president of research at Dean Witter Reynolds, having begun his career on Wall Street as an analyst and investment banker at EF Hutton. In 2002, Dr. Armen founded the Children of Armenia Fund, a nonprofit organization dedicated to significantly rebuilding and revitalizing impoverished rural Armenian towns to provide immediate and stainable benefits to children and youth. He received the Ellis Island Medal of Honor in 2004 for his humanitarian efforts, and received the Sabin Humanitarian Award from the Sabin Vaccine Institute in 2006 for his achievements in biotechnology and progressing medical research. Dr. Armen was also the Ernst & Young 2002 New York City Biotechnology Entrepreneur of the Year, and received a Wings of Hope Award in 2005 from The Melanoma Research Foundation for his ongoing commitment to the melanoma community. Dr. Armen received a PhD in physical chemistry from the Graduate Center, City University of New York, after which he worked as a research fellow at Brookhaven National Laboratories in Long Island, NY.
- Brian Corvese
-
Brian Corvese，自1999年以来，他一直担任Vencor Capital（一家在中东和地中海地区进行电信和技术投资的私募股权公司）的总裁和创始人。在Vencor工作之前，他曾担任索罗斯基金管理公司（当时世界上最大的对冲基金）的董事总经理和合伙人，从事美国和全球股票市场的投资。从1988年到1996年，他是Chancellor Capital Management（一家250亿美元的资金管理公司）的合伙人。在Chancellor任职期间，他曾担任投资组合经理，负责基础行业、重组、特殊情况、公司治理投资的投资，以及创立和管理自己的对冲基金。从1981年到1988年，Corvese先生在Drexel Burnham Lambert（“Drexel”）担任股票分析师，跟踪化学和特种化学行业，并参与了大量的并购活动。在Drexel任职期间，他是机构投资者（Institutional Investor）排名的顶级化学和特种化学研究团队的成员。他目前担任MiNK Therapeutics， Inc.（位于埃及开罗的国家电信公司）和Protagenic Therapeutics （Agenus的子公司，位于加拿大安大略省）的董事会成员。他获得Rhode Island大学的金融和政治学学位，并就读于纽约大学研究生院。
Brian Corvese,has been the President and Founder of Vencor Capital ("Vencor"), a private equity firm with telecommunications and technology investments in the Middle East and Mediterranean regions. Prior to working at Vencor, Mr. Corvese worked on investments in the U.S. and global equity markets as a Managing Director and partner at Soros Fund Management, the largest hedge fund in the world at the time. From 1988 to 1996, Mr. Corvese was a partner at Chancellor Capital Management ("Chancellor"), a $25 billion money management firm. While at Chancellor, Mr. Corvese was a Portfolio Manager with responsibility for investments made in basic industries, restructurings, and special situations, corporate governance investments, as well as founded and managed his own hedge fund. From 1981 to 1988, Mr. Corvese was with Drexel Burnham Lambert ("Drexel") as an equity analyst following the chemical and specialty chemical industries and participated in a significant number of merger and acquisition activities. While at Drexel, Mr. Corvese was a member of the top chemical and specialty chemical research team, as ranked by Institutional Investor. In addition to serving on the Board of MiNK, Mr. Corvese currently serves on the Board of Directors of Agenus , the National Telecommunications Corporation, based in Cairo, Egypt, and Protagenic Therapeutics based in Ontario, Canada. Mr. Corvese earned degrees in finance and political science from The University of Rhode Island and attended New York University Graduate School. - Brian Corvese，自1999年以来，他一直担任Vencor Capital（一家在中东和地中海地区进行电信和技术投资的私募股权公司）的总裁和创始人。在Vencor工作之前，他曾担任索罗斯基金管理公司（当时世界上最大的对冲基金）的董事总经理和合伙人，从事美国和全球股票市场的投资。从1988年到1996年，他是Chancellor Capital Management（一家250亿美元的资金管理公司）的合伙人。在Chancellor任职期间，他曾担任投资组合经理，负责基础行业、重组、特殊情况、公司治理投资的投资，以及创立和管理自己的对冲基金。从1981年到1988年，Corvese先生在Drexel Burnham Lambert（“Drexel”）担任股票分析师，跟踪化学和特种化学行业，并参与了大量的并购活动。在Drexel任职期间，他是机构投资者（Institutional Investor）排名的顶级化学和特种化学研究团队的成员。他目前担任MiNK Therapeutics， Inc.（位于埃及开罗的国家电信公司）和Protagenic Therapeutics （Agenus的子公司，位于加拿大安大略省）的董事会成员。他获得Rhode Island大学的金融和政治学学位，并就读于纽约大学研究生院。
- Brian Corvese,has been the President and Founder of Vencor Capital ("Vencor"), a private equity firm with telecommunications and technology investments in the Middle East and Mediterranean regions. Prior to working at Vencor, Mr. Corvese worked on investments in the U.S. and global equity markets as a Managing Director and partner at Soros Fund Management, the largest hedge fund in the world at the time. From 1988 to 1996, Mr. Corvese was a partner at Chancellor Capital Management ("Chancellor"), a $25 billion money management firm. While at Chancellor, Mr. Corvese was a Portfolio Manager with responsibility for investments made in basic industries, restructurings, and special situations, corporate governance investments, as well as founded and managed his own hedge fund. From 1981 to 1988, Mr. Corvese was with Drexel Burnham Lambert ("Drexel") as an equity analyst following the chemical and specialty chemical industries and participated in a significant number of merger and acquisition activities. While at Drexel, Mr. Corvese was a member of the top chemical and specialty chemical research team, as ranked by Institutional Investor. In addition to serving on the Board of MiNK, Mr. Corvese currently serves on the Board of Directors of Agenus , the National Telecommunications Corporation, based in Cairo, Egypt, and Protagenic Therapeutics based in Ontario, Canada. Mr. Corvese earned degrees in finance and political science from The University of Rhode Island and attended New York University Graduate School.
- Timothy R. Wright
-
Timothy R. Wright，他自2019年4月以来一直担任Isosceles的执行主席。他还担任BIORG， INC 。的总裁兼首席执行官（2013年11月以来）。在担任这些职位之前，他是MiMedX（再生医学公司）的首席执行官。他目前还担任Agenus Inc.的董事会成员（2006年以来）。此外，他是the Ohio State University Comprehensive Cancer Center Drug Development Institute的创始人和前任主席。他还担任Washington University Medical School和North Carolina Veterinary School的顾问委员会成员。Wright先生曾在Covidien（现为Medtronic）、Teva Pharmaceuticals Industries Ltd.、DuPont Merck、Elan Bio-Pharmaceuticals、M2Gen Corp.担任多个行政职务。
Timothy R. Wright is the Chief Executive Officer of MiMedX Group, Inc., a position that he has held since May 2019. MiMedX is an advanced wound care and emerging therapeutic biologics company. Mr. Wright also currently serves on the board of directors of Agen Inc., which he has served on since 2006. Mr. Wright also serves as a Partner at Signal Hill Advisors, LLC, a position he has held since February 2011. In addition, Mr. Wright serves as Chairman of The Ohio State University Comprehensive Cancer Center Drug Development Institute and Director of the Ohio State University Innovation Foundation. Mr. Wright previoly held several executive roles at Covidien (now Medtronic), Teva Pharmaceuticals Indtries Ltd., DuPont Merck, Elan Bio Pharmaceuticals, M2Gen Corp. and Curaxis Pharmaceuticals Corporation. - Timothy R. Wright，他自2019年4月以来一直担任Isosceles的执行主席。他还担任BIORG， INC 。的总裁兼首席执行官（2013年11月以来）。在担任这些职位之前，他是MiMedX（再生医学公司）的首席执行官。他目前还担任Agenus Inc.的董事会成员（2006年以来）。此外，他是the Ohio State University Comprehensive Cancer Center Drug Development Institute的创始人和前任主席。他还担任Washington University Medical School和North Carolina Veterinary School的顾问委员会成员。Wright先生曾在Covidien（现为Medtronic）、Teva Pharmaceuticals Industries Ltd.、DuPont Merck、Elan Bio-Pharmaceuticals、M2Gen Corp.担任多个行政职务。
- Timothy R. Wright is the Chief Executive Officer of MiMedX Group, Inc., a position that he has held since May 2019. MiMedX is an advanced wound care and emerging therapeutic biologics company. Mr. Wright also currently serves on the board of directors of Agen Inc., which he has served on since 2006. Mr. Wright also serves as a Partner at Signal Hill Advisors, LLC, a position he has held since February 2011. In addition, Mr. Wright serves as Chairman of The Ohio State University Comprehensive Cancer Center Drug Development Institute and Director of the Ohio State University Innovation Foundation. Mr. Wright previoly held several executive roles at Covidien (now Medtronic), Teva Pharmaceuticals Indtries Ltd., DuPont Merck, Elan Bio Pharmaceuticals, M2Gen Corp. and Curaxis Pharmaceuticals Corporation.
高管简历
中英对照 | 中文 | 英文- Andrew Slee
Andrew Slee于2016年4月加入我们。在他37年的制药职业生涯中，Slee先生从一开始就服用了几种药物，直到他们所有的临床前和早期临床测试。在过去的37年中，他曾任职于临床前CRO、免疫肿瘤学公司和专注于抗感染、癌症、CNS、糖尿病和炎症性疾病的天然产品公司。将他的影响力扩展到单个公司之外，他创立并经营自己的合同研究组织CRO，VivoSource Laboratories，从2003年到2013年的十年时间里为生物制药公司提供了概念的临床前证明。在此之前的18年中，Slee博士从杜邦制药公司（DuPont Pharmaceuticals）成立之初就在多个治疗领域领导多个制药目标。他是Syracuse University和Leeds University的毕业生。
Andrew Slee joined Protagenic Therapeutics, Inc. in April 2016. During his 37-year pharmaceutical career, Mr. Slee has taken several drugs from inception through all their pre-clinical and early clinical testing. During the past 37 years, he has worked for Preclinical CROs, immune-oncology companies and natural product companies focusing on anti-infectives, cancer, CNS, diabetes and inflammatory diseases. Spreading his influence beyond a single company, he created and ran his own Contract Research Organization (CRO), VivoSource Laboratories, which for ten years from 2003 to 2013 provided preclinical proof of concept catering to biopharmaceutical companies. For the 18 years before that, Mr. Slee shepherded multiple pharma targets in several therapeutic areas from inception onward at DuPont Pharmaceuticals. He is a graduate of Syracuse University and Leeds University.- Andrew Slee于2016年4月加入我们。在他37年的制药职业生涯中，Slee先生从一开始就服用了几种药物，直到他们所有的临床前和早期临床测试。在过去的37年中，他曾任职于临床前CRO、免疫肿瘤学公司和专注于抗感染、癌症、CNS、糖尿病和炎症性疾病的天然产品公司。将他的影响力扩展到单个公司之外，他创立并经营自己的合同研究组织CRO，VivoSource Laboratories，从2003年到2013年的十年时间里为生物制药公司提供了概念的临床前证明。在此之前的18年中，Slee博士从杜邦制药公司（DuPont Pharmaceuticals）成立之初就在多个治疗领域领导多个制药目标。他是Syracuse University和Leeds University的毕业生。
- Andrew Slee joined Protagenic Therapeutics, Inc. in April 2016. During his 37-year pharmaceutical career, Mr. Slee has taken several drugs from inception through all their pre-clinical and early clinical testing. During the past 37 years, he has worked for Preclinical CROs, immune-oncology companies and natural product companies focusing on anti-infectives, cancer, CNS, diabetes and inflammatory diseases. Spreading his influence beyond a single company, he created and ran his own Contract Research Organization (CRO), VivoSource Laboratories, which for ten years from 2003 to 2013 provided preclinical proof of concept catering to biopharmaceutical companies. For the 18 years before that, Mr. Slee shepherded multiple pharma targets in several therapeutic areas from inception onward at DuPont Pharmaceuticals. He is a graduate of Syracuse University and Leeds University.
- Robert B. Stein
Robert B. Stein于2022年4月被任命为再生医学和生物制剂创新总裁。他于2020年8月加入Comany，担任研发执行副总裁。斯坦博士在杜克大学获得生理学和药理学的医学博士和博士学位，在印第安纳大学获得生物学和化学的学士学位。在住院后，斯坦因博士于1982年至1990年在默沙东、夏普和多姆研究实验室担任越来越重要的职务，为三种新产品做出了贡献：Cozaar（一种处方药）、Sustiva（一种HIV抗病毒药物）和Gardasil（一种疫苗）。从1990年到1996年，他担任Ligand制药公司的第一任研发主管。1996年，他成为杜邦-默克和杜邦制药公司的研究和临床前开发执行副总裁，促成了Sustiva和Innohep的注册，以及重磅炸弹Eliquis的发现和发展，随后被百时美施贵宝公司注册。在Bristol Myers Squibb收购杜邦之后，2001年11月至2003年9月，他担任因塞特医疗制药公司总裁、研发和首席科学官。2003年9月至2007年1月，他担任罗氏帕洛阿尔托有限责任公司总裁。2008年8月至2010年5月，他担任转化医学公司Kinemed, Inc.的首席执行官。继Kinemed之后，他于2014年1月至2015年9月担任首席科学官，并于2015年9月至2017年3月担任免疫肿瘤公司Agenus Inc的研发总裁。随后，他于2017年3月至2019年10月担任Agenus和AgenTus的全职研发高级顾问。在此期间，Agenus将13个单克隆抗体推进临床，并与因塞特医疗、默沙东、UCB和吉利德建立了重要的合作关系。
Robert B. Stein,joined Protagenic Therapeutics, Inc. effective the closing of the Merger in February, 2016. Dr. Robert B. Stein is Chief Scientific Officer of Agenus Inc. Dr. Robert B. Stein leads Agenus' Research, Preclinical Development and Translational Medicine functions. He helps shape clinical development strategy for vaccines and adjuvants. Additionally, he's leading integration of the 4-Antibody acquisition, which includes the company's fully human antibody drug discovery and optimization technology platform, and portfolio of immune checkpoint antibody programs. Over his 30 years of experience in the biopharmaceutical industry he played a pivotal role in bringing to the market Sustiva, Fablyn, Viviant, PanRetin, TargRetin, Promacta and Eliquis. Prior to joining Agenus, he held executive management positions at Ligand Pharmaceuticals, DuPont Merck, Incyte Pharmaceuticals, Roche Palo Alto and KineMed. Dr. Stein began his career at Merck, Sharp and Dohme. He holds an MD and a PhD in Physiology & Pharmacology from Duke University. Dr. Stein filed a personal voluntary bankruptcy petition under Chapter 7 in August of 2012 and the bankruptcy was discharged in May 2013. Dr. Stein brings substantial scientific expertise to Protagenic Therapeutics, Inc. Board.- Robert B. Stein于2022年4月被任命为再生医学和生物制剂创新总裁。他于2020年8月加入Comany，担任研发执行副总裁。斯坦博士在杜克大学获得生理学和药理学的医学博士和博士学位，在印第安纳大学获得生物学和化学的学士学位。在住院后，斯坦因博士于1982年至1990年在默沙东、夏普和多姆研究实验室担任越来越重要的职务，为三种新产品做出了贡献：Cozaar（一种处方药）、Sustiva（一种HIV抗病毒药物）和Gardasil（一种疫苗）。从1990年到1996年，他担任Ligand制药公司的第一任研发主管。1996年，他成为杜邦-默克和杜邦制药公司的研究和临床前开发执行副总裁，促成了Sustiva和Innohep的注册，以及重磅炸弹Eliquis的发现和发展，随后被百时美施贵宝公司注册。在Bristol Myers Squibb收购杜邦之后，2001年11月至2003年9月，他担任因塞特医疗制药公司总裁、研发和首席科学官。2003年9月至2007年1月，他担任罗氏帕洛阿尔托有限责任公司总裁。2008年8月至2010年5月，他担任转化医学公司Kinemed, Inc.的首席执行官。继Kinemed之后，他于2014年1月至2015年9月担任首席科学官，并于2015年9月至2017年3月担任免疫肿瘤公司Agenus Inc的研发总裁。随后，他于2017年3月至2019年10月担任Agenus和AgenTus的全职研发高级顾问。在此期间，Agenus将13个单克隆抗体推进临床，并与因塞特医疗、默沙东、UCB和吉利德建立了重要的合作关系。
- Robert B. Stein,joined Protagenic Therapeutics, Inc. effective the closing of the Merger in February, 2016. Dr. Robert B. Stein is Chief Scientific Officer of Agenus Inc. Dr. Robert B. Stein leads Agenus' Research, Preclinical Development and Translational Medicine functions. He helps shape clinical development strategy for vaccines and adjuvants. Additionally, he's leading integration of the 4-Antibody acquisition, which includes the company's fully human antibody drug discovery and optimization technology platform, and portfolio of immune checkpoint antibody programs. Over his 30 years of experience in the biopharmaceutical industry he played a pivotal role in bringing to the market Sustiva, Fablyn, Viviant, PanRetin, TargRetin, Promacta and Eliquis. Prior to joining Agenus, he held executive management positions at Ligand Pharmaceuticals, DuPont Merck, Incyte Pharmaceuticals, Roche Palo Alto and KineMed. Dr. Stein began his career at Merck, Sharp and Dohme. He holds an MD and a PhD in Physiology & Pharmacology from Duke University. Dr. Stein filed a personal voluntary bankruptcy petition under Chapter 7 in August of 2012 and the bankruptcy was discharged in May 2013. Dr. Stein brings substantial scientific expertise to Protagenic Therapeutics, Inc. Board.
- Garo H. Armen
Garo H. Armen是Protagenic治疗公司的创始人之一，于2004年9月加入Protagenic治疗公司。Garo H. Armen是Agenus Inc.的董事长兼首席执行官，他在1994年与他人共同创立了一家生物技术公司。从2002年中到2004年，他还担任了成功重组的生物制药公司Elan Corporation，plc的董事会主席。在加入Agenus Inc.之前，Armen博士创立了Armen Partners，这是一家专门从事生物技术和制药公司业务的资金管理公司，并且是1993年创立Immunex Lederle肿瘤学公司这一广为人知的项目的设计者。在更早之前，他是Dean Witter Reynolds研究部高级副总裁，他的职业生涯始于华尔街，在EF Hutton担任分析师和投资银行家。2002年，Armen博士创立了亚美尼亚儿童基金会，这是一个非营利组织，致力于大力重建和振兴贫困的亚美尼亚农村城镇，为儿童和青年提供直接和可持续的利益。由于他的人道主义努力，他于2004年获得埃利斯岛荣誉勋章；由于他在生物技术和医学研究方面取得的成就，他于2006年获得萨宾疫苗研究所颁发的萨宾人道主义奖。Armen博士也是安永会计师事务所2002年纽约市年度生物技术企业家，并于2005年获得黑素瘤研究基金会颁发的希望之翼奖，以表彰他对黑素瘤社区的持续承诺。Armen博士在纽约城市大学研究生中心获得物理化学博士学位，之后他在纽约长岛的Brookhaven国家实验室担任研究员。
Garo H. Armen, Executive Chairman, is one of founders and joined in September 2004. Garo H. Armen is Chairman and Chief Executive Officer of Agen Inc., a biotechnology company he co founded in 1994. From mid 2002 through 2004, he also served as Chairman of the Board of the biopharmaceutical company Elan Corporation, plc, which he successfully restructured. Prior to Agen Inc., Dr. Armen established Armen Partners, a money management firm specializing in biotechnology and pharmaceutical companies and was the architect of the widely publicized creation of the Immunex Lederle oncology biness in 1993. Earlier, he was a senior vice president of research at Dean Witter Reynolds, having begun his career on Wall Street as an analyst and investment banker at EF Hutton. In 2002, Dr. Armen founded the Children of Armenia Fund, a nonprofit organization dedicated to significantly rebuilding and revitalizing impoverished rural Armenian towns to provide immediate and stainable benefits to children and youth. He received the Ellis Island Medal of Honor in 2004 for his humanitarian efforts, and received the Sabin Humanitarian Award from the Sabin Vaccine Institute in 2006 for his achievements in biotechnology and progressing medical research. Dr. Armen was also the Ernst & Young 2002 New York City Biotechnology Entrepreneur of the Year, and received a Wings of Hope Award in 2005 from The Melanoma Research Foundation for his ongoing commitment to the melanoma community. Dr. Armen received a PhD in physical chemistry from the Graduate Center, City University of New York, after which he worked as a research fellow at Brookhaven National Laboratories in Long Island, NY.- Garo H. Armen是Protagenic治疗公司的创始人之一，于2004年9月加入Protagenic治疗公司。Garo H. Armen是Agenus Inc.的董事长兼首席执行官，他在1994年与他人共同创立了一家生物技术公司。从2002年中到2004年，他还担任了成功重组的生物制药公司Elan Corporation，plc的董事会主席。在加入Agenus Inc.之前，Armen博士创立了Armen Partners，这是一家专门从事生物技术和制药公司业务的资金管理公司，并且是1993年创立Immunex Lederle肿瘤学公司这一广为人知的项目的设计者。在更早之前，他是Dean Witter Reynolds研究部高级副总裁，他的职业生涯始于华尔街，在EF Hutton担任分析师和投资银行家。2002年，Armen博士创立了亚美尼亚儿童基金会，这是一个非营利组织，致力于大力重建和振兴贫困的亚美尼亚农村城镇，为儿童和青年提供直接和可持续的利益。由于他的人道主义努力，他于2004年获得埃利斯岛荣誉勋章；由于他在生物技术和医学研究方面取得的成就，他于2006年获得萨宾疫苗研究所颁发的萨宾人道主义奖。Armen博士也是安永会计师事务所2002年纽约市年度生物技术企业家，并于2005年获得黑素瘤研究基金会颁发的希望之翼奖，以表彰他对黑素瘤社区的持续承诺。Armen博士在纽约城市大学研究生中心获得物理化学博士学位，之后他在纽约长岛的Brookhaven国家实验室担任研究员。
- Garo H. Armen, Executive Chairman, is one of founders and joined in September 2004. Garo H. Armen is Chairman and Chief Executive Officer of Agen Inc., a biotechnology company he co founded in 1994. From mid 2002 through 2004, he also served as Chairman of the Board of the biopharmaceutical company Elan Corporation, plc, which he successfully restructured. Prior to Agen Inc., Dr. Armen established Armen Partners, a money management firm specializing in biotechnology and pharmaceutical companies and was the architect of the widely publicized creation of the Immunex Lederle oncology biness in 1993. Earlier, he was a senior vice president of research at Dean Witter Reynolds, having begun his career on Wall Street as an analyst and investment banker at EF Hutton. In 2002, Dr. Armen founded the Children of Armenia Fund, a nonprofit organization dedicated to significantly rebuilding and revitalizing impoverished rural Armenian towns to provide immediate and stainable benefits to children and youth. He received the Ellis Island Medal of Honor in 2004 for his humanitarian efforts, and received the Sabin Humanitarian Award from the Sabin Vaccine Institute in 2006 for his achievements in biotechnology and progressing medical research. Dr. Armen was also the Ernst & Young 2002 New York City Biotechnology Entrepreneur of the Year, and received a Wings of Hope Award in 2005 from The Melanoma Research Foundation for his ongoing commitment to the melanoma community. Dr. Armen received a PhD in physical chemistry from the Graduate Center, City University of New York, after which he worked as a research fellow at Brookhaven National Laboratories in Long Island, NY.
- Alexander K. Arrow
Alexander K. Arrow于2016年2月成为Protagenic Therapeutics, Inc.首席财务官。Arrow博士是Carlsmed，Inc.的首席财务官，Carlsmed，Inc.是一家脊柱植入物制造商，其使命是改善预后，降低脊柱手术及其他手术的医疗保健费用。他在处于发展阶段的眼科工具公司Insightful Instruments，Inc.和领先的固体器官运输设备供应商Paragonix Technologies的董事会任职。在此之前，Arrow博士曾担任Neumedicines，Inc.的董事，该公司开发肿瘤、血液学和免疫学领域的蛋白质疗法，从2010年到2014年担任Biolase, Inc.（纳斯达克股票代码：BIOL）审计委员会和薪酬委员会的董事和主席，以及总裁兼首席运营官。Biolase公司是牙科激光器的领先制造商。在Biolase之前，他是Circuit Therapeutics，Inc.在光遗传学领域的首席医疗和战略官。从2007年到2012年，Arrow博士在心脏病学设备制造商Arstasis公司担任首席财务官。2002年至2007年，他在全球投资银行Lazard Capital markets，LLC担任医疗技术股票研究主管。从1999年到2001年，Arrow博士在美国专利与许可交易所担任了两年首席财务官，在韦德布什摩根证券公司担任了三年生命科学研究分析师。他于1999年获得CFA学位。他于1996年获得哈佛医学院的医学博士学位，并于1992年以优异成绩获得康奈尔大学的生物物理学学士学位。
Alexander K. Arrow,became Protagenic Therapeutics, Inc. Chief Financial Officer in February 2016. Dr. Arrow is the Chief Financial Officer of Strateos, Inc., a life sciences robotics company serving the pharmaceutical industry. He was previously the CFO of Carlsmed, Inc., a spinal implant manufacturer providing 3-D printed personalized spinal implants to spine surgeons. He serves on the Board of Directors of Insightful Instruments, Inc., a developmental stage ophthalmology tool company. He previously served on the Boards of Paragonix Technologies, supplier of the leading solid organ transportation device, and Neumedicines, Inc., a company developing protein therapeutics in Oncology, Hematology and Immunology, and as a director and as Chairman of the Audit and Compensation Committees of Biolase, Inc. (NASDAQ: BIOL) from 2010 through 2014, as well as the President and Chief Operating Officer. Biolase, Inc. is the leading manufacturer of dental lasers. Before Biolase, he was the Chief Medical and Strategic Officer of Circuit Therapeutics, Inc., in the field of optogenetics. From 2007 through 2012, Dr. Arrow was the Chief Financial Officer of Arstasis, Inc., a cardiology device manufacturer. From 2002 to 2007, he headed medical technology equity research at the global investment bank Lazard Capital markets, LLC. Dr. Arrow spent two years 1999-2001 as Chief Financial Officer of the Patent & License Exchange, and three years as the life sciences research analyst at Wedbush Morgan Securities. He received his CFA in 1999. He was awarded an M.D. from Harvard Medical School in 1996 and a B.A. in Biophysics, magna cum laude, from Cornell University in 1992.- Alexander K. Arrow于2016年2月成为Protagenic Therapeutics, Inc.首席财务官。Arrow博士是Carlsmed，Inc.的首席财务官，Carlsmed，Inc.是一家脊柱植入物制造商，其使命是改善预后，降低脊柱手术及其他手术的医疗保健费用。他在处于发展阶段的眼科工具公司Insightful Instruments，Inc.和领先的固体器官运输设备供应商Paragonix Technologies的董事会任职。在此之前，Arrow博士曾担任Neumedicines，Inc.的董事，该公司开发肿瘤、血液学和免疫学领域的蛋白质疗法，从2010年到2014年担任Biolase, Inc.（纳斯达克股票代码：BIOL）审计委员会和薪酬委员会的董事和主席，以及总裁兼首席运营官。Biolase公司是牙科激光器的领先制造商。在Biolase之前，他是Circuit Therapeutics，Inc.在光遗传学领域的首席医疗和战略官。从2007年到2012年，Arrow博士在心脏病学设备制造商Arstasis公司担任首席财务官。2002年至2007年，他在全球投资银行Lazard Capital markets，LLC担任医疗技术股票研究主管。从1999年到2001年，Arrow博士在美国专利与许可交易所担任了两年首席财务官，在韦德布什摩根证券公司担任了三年生命科学研究分析师。他于1999年获得CFA学位。他于1996年获得哈佛医学院的医学博士学位，并于1992年以优异成绩获得康奈尔大学的生物物理学学士学位。
- Alexander K. Arrow,became Protagenic Therapeutics, Inc. Chief Financial Officer in February 2016. Dr. Arrow is the Chief Financial Officer of Strateos, Inc., a life sciences robotics company serving the pharmaceutical industry. He was previously the CFO of Carlsmed, Inc., a spinal implant manufacturer providing 3-D printed personalized spinal implants to spine surgeons. He serves on the Board of Directors of Insightful Instruments, Inc., a developmental stage ophthalmology tool company. He previously served on the Boards of Paragonix Technologies, supplier of the leading solid organ transportation device, and Neumedicines, Inc., a company developing protein therapeutics in Oncology, Hematology and Immunology, and as a director and as Chairman of the Audit and Compensation Committees of Biolase, Inc. (NASDAQ: BIOL) from 2010 through 2014, as well as the President and Chief Operating Officer. Biolase, Inc. is the leading manufacturer of dental lasers. Before Biolase, he was the Chief Medical and Strategic Officer of Circuit Therapeutics, Inc., in the field of optogenetics. From 2007 through 2012, Dr. Arrow was the Chief Financial Officer of Arstasis, Inc., a cardiology device manufacturer. From 2002 to 2007, he headed medical technology equity research at the global investment bank Lazard Capital markets, LLC. Dr. Arrow spent two years 1999-2001 as Chief Financial Officer of the Patent & License Exchange, and three years as the life sciences research analyst at Wedbush Morgan Securities. He received his CFA in 1999. He was awarded an M.D. from Harvard Medical School in 1996 and a B.A. in Biophysics, magna cum laude, from Cornell University in 1992.